Botulinum toxins in the treatment of primary focal dystonias

Journal of the Neurological Sciences

Volumn 316, Issue 1-2, 2012, Pages 9-14

  Truong, Daniel ^a  

^a Parkinson's and Movement Disorder Institute   (United States)

Author keywords

AbobotulinumtoxinA; Blepharospasm; Botulinum toxin; Dystonia; Focal dystonia; IncobotulinumtoxinA; OnabotulinumtoxinA; RimabotulinumB

Indexed keywords

BENZODIAZEPINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; LEVODOPA; MEDITOXIN; NEURONOX; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; BLEPHAROSPASM; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FLU LIKE SYNDROME; HEMIFACIAL SPASM; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; NECK PAIN; PRIORITY JOURNAL; PTOSIS; SINUSITIS; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 84859438392     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.01.019     Document Type: Review

References (95)

1. A. Albanese, and S. Lalli Is this dystonia? Mov Disord 24 12 2009 1725 1731
2. A. Albanese, F. Asmus, K.P. Bhatia, A.E. Elia, B. Elibol, and G. Filippini EFNS guidelines on diagnosis and treatment of primary dystonias Eur J Neurol 18 1 2011 5 18
3. G. Defazio The epidemiology of primary dystonia: current evidence and perspectives Eur J Neurol 17 Suppl 1 2010 9 14
4. A. Schmidt, and C. Klein The role of genes in causing dystonia Eur J Neurol 17 Suppl 1 2010 65 70
5. N. Sharma, R.A. Franco, J.K. Kuster, A.A. Mitchell, T. Fuchs, and R. Saunders-Pullman Genetic evidence for an association of the TOR1A locus with segmental/focal dystonia Mov Disord 25 13 2010 2183 2187
6. M. Stacy Epidemiology, clinical presentation, and diagnosis of cervical dystonia Neurol Clin 26 Suppl 1 2008 23 42
7. A. Albanese, M.P. Barnes, K.P. Bhatia, E. Fernandez-Alvarez, G. Filippini, and T. Gasser A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force Eur J Neurol 13 5 2006 433 444
8. R. Benecke, and D. Dressler Botulinum toxin treatment of axial and cervical dystonia Disabil Rehabil 29 23 2007 1769 1777
9. D.M. Simpson, A. Blitzer, A. Brashear, C. Comella, R. Dubinsky, and M. Hallett Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 70 19 2008 1699 1706
10. Allergan Inc Package insert, BOTOX (Botulinum toxin type A purified neurotoxin complex) 2000 Irvine Allergan Inc.
11. Ipsen Biopharm Ltd Dysport prescribing information 2009
12. Merz Pharmaceuticals, LLC Xeomin prescribing information 2010
13. Solstice Neurosciences Inc Myobloc prescribing information 2010
14. U.S. Food and Drug Administration Botox and Botox cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B) [cited 2011 December 29]; available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm164255.htm 2009
15. D. Dressler, and R. Benecke Pharmacology of therapeutic botulinum toxin preparations Disabil Rehabil 29 23 2007 1761 1768
16. J. Frevert Xeomin is free from complexing proteins Toxicon 54 5 2009 697 701
17. A. Albanese Terminology for preparations of botulinum neurotoxins: what a difference a name makes JAMA 305 1 2011 89 90
18. S. Gollomp Neurotoxin therapy: a closer look at the four options Pract Neurol 2011;(March/April):27-33
19. J.K. Tsui, A. Eisen, E. Mak, J. Carruthers, A. Scott, and D.B. Calne A pilot study on the use of botulinum toxin in spasmodic torticollis Can J Neurol Sci 12 4 1985 314 316
20. J.K. Tsui, A. Eisen, A.J. Stoessl, S. Calne, and D.B. Calne Double-blind study of botulinum toxin in spasmodic torticollis Lancet 2 8501 1986 245 247
21. A.B. Scott, R.A. Kennedy, and H.A. Stubbs Botulinum A toxin injection as a treatment for blepharospasm Arch Ophthalmol 103 3 1985 347 350
22. C.L. Comella The treatment of cervical dystonia with botulinum toxins J Neural Transm 115 4 2008 579 583
23. M. Brainin, M. Barnes, J.C. Baron, N.E. Gilhus, R. Hughes, and K. Selmaj Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004 Eur J Neurol 11 9 2004 577 581
24. J.W. Brans, R. Lindeboom, J.W. Snoek, M.J. Zwarts, T.W. van Weerden, and E.R. Brunt Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial Neurology 46 4 1996 1066 1072
25. A. Brashear, M.F. Lew, D.D. Dykstra, C.L. Comella, S.A. Factor, and R.L. Rodnitzky Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia Neurology 53 7 1999 1439 1446
26. M.F. Brin, M.F. Lew, C.H. Adler, C.L. Comella, S.A. Factor, and J. Jankovic Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia Neurology 53 7 1999 1431 1438
27. P. Greene, U. Kang, S. Fahn, M. Brin, C. Moskowitz, and E. Flaster Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis Neurology 40 8 1990 1213 1218
28. M.F. Lew, B.T. Adornato, D.D. Duane, D.D. Dykstra, S.A. Factor, and J.M. Massey Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia Neurology 49 3 1997 701 707
29. W. Poewe, G. Deuschl, A. Nebe, E. Feifel, J. Wissel, and R. Benecke What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group J Neurol Neurosurg Psychiatry 64 1 1998 13 17
30. D. Truong, M. Brodsky, M. Lew, A. Brashear, J. Jankovic, and E. Molho Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia Parkinsonism Relat Disord 16 5 2010 316 323
31. D. Truong, D.D. Duane, J. Jankovic, C. Singer, L.C. Seeberger, and C.L. Comella Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study Mov Disord 20 7 2005 783 791
32. R. Hughes, and B.C. Whaler Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin J Physiol 160 1962 221 233
33. H.S. Kim, J.H. Hwang, S.T. Jeong, Y.T. Lee, P.K. Lee, and Y.L. Suh Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis Dev Med Child Neurol 45 3 2003 200 206
34. R. Eleopra, V. Tugnoli, and D. De Grandis The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans Mov Disord 12 1 1997 89 94
35. E. Frasson, A. Priori, B. Ruzzante, G. Didone, and L. Bertolasi Nerve stimulation boosts botulinum toxin action in spasticity Mov Disord 20 5 2005 624 629
36. S. Hesse, F. Reiter, M. Konrad, and M.T. Jahnke Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial Clin Rehabil 12 5 1998 381 388
37. M.F. Brin, S. Fahn, C. Moskowitz, A. Friedman, H.M. Shale, and P.E. Greene Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm Mov Disord 2 4 1987 237 254
38. D.J. Gelb, D.H. Lowenstein, and M.J. Aminoff Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis Neurology 39 1 1989 80 84
39. J. Jankovic, and K. Schwartz Botulinum toxin injections for cervical dystonia Neurology 40 2 1990 277 280
40. J.S. Elston Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections Br J Ophthalmol 71 9 1987 664 668
41. P. Roggenkämper, W.H. Jost, K. Bihari, G. Comes, and S. Grafe Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm J Neural Transm 113 3 2006 303 312
42. J.C. Tan Practical manual of physical medicine and rehabilitation 2nd ed. 2006 Mosby St Louis 507
43. J. Wissel, P. Kanovsky, E. Ruzicka, M. Bares, H. Hortova, and H. Streitova Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study J Neurol 248 12 2001 1073 1078
44. K.R. Kessler, M. Skutta, and R. Benecke Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group J Neurol 246 4 1999 265 274
45. D. Truong, C. Comella, H.H. Fernandez, and W.G. Ondo Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial Parkinsonism Relat Disord 14 5 2008 407 414
46. T. Odergren, H. Hjaltason, S. Kaakkola, G. Solders, J. Hanko, and C. Fehling A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia J Neurol Neurosurg Psychiatry 64 1 1998 6 12
47. Z. Nüssgens, and P. Roggenkämper Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm Graefes Arch Clin Exp Ophthalmol 235 4 1997 197 199
48. A.R. Bentivoglio, A. Fasano, T. Ialongo, F. Soleti, S. Lo Fermo, and A. Albanese Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs Neurotox Res 15 3 2009 224 231
49. D. Ranoux, C. Gury, J. Fondarai, J.L. Mas, and M. Zuber Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia J Neurol Neurosurg Psychiatry 72 4 2002 459 462
50. K. Bihari Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm Curr Med Res Opin 21 3 2005 433 438
51. R. Benecke, W.H. Jost, P. Kanovsky, E. Ruzicka, G. Comes, and S. Grafe A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia Neurology 64 11 2005 1949 1951
52. S. Grafe, G. Comes, and I. Sassin Clinical efficacy in focal dystonia and overall tolerability of NT 201 (botulinum neurotoxin free from complexing proteins) [abstract] Neurology 72 Suppl 3 2009 A344
53. W.H. Jost, J. Blumel, and S. Grafe Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia Drugs 67 5 2007 669 683
54. A. Le Henanff, B. Giraudeau, G. Baron, and P. Ravaud Quality of reporting of noninferiority and equivalence randomized trials JAMA 295 10 2006 1147 1151
55. J. Jankovic, and J. Orman Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study Neurology 37 4 1987 616 623
56. R. Goertelmeyer, S. Brinkmann, G. Comes, and A. Delcker The Blepharospasm Disability Index (BSDI) for the assessment of functional health in focal dystonia Clin Neurophysiol 113 Suppl 1 2002 S77 S78
57. J. Wissel, J. Muller, J. Dressnandt, F. Heinen, M. Naumann, and H. Topka Management of spasticity associated pain with botulinum toxin A J Pain Symptom Manage 20 1 2000 44 49
58. C. Comella, J. Jankovic, D. Truong, A. Hanschmann, and S. Grafe Efficacy and safety of NT 201 (neurotoxin free from complexing proteins) in cervical dystonia Neurology 72 Suppl 3 2009 A345
59. S. Grafe, C. Comella, J. Jankovic, D. Truong, and A. Hanschmann Efficacy and safety of NT 201: botulinum neurotoxin type A free from complexing proteins, in treatment-naive cervical dystonia patients [abstract] Mov Disord 24 Suppl 1 2009 S92 S93
60. S. Grafe, C. Comella, and J. Jankovic Efficacy and safety of NT 201: botulinum neurotoxin type A free from complexing proteins, in treatment-naive cervial dystonia patients [abstract] Mov Disord 24 Suppl 1 2009 S92 S93
61. S. Grafe, and A. Hanschmann Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with cervical dystonia: a first long-term safety analysis [abstract] Neurology 74 Suppl 2 2010 A88
62. J. Jankovic, C. Comella, A. Hanschmann, and S. Grafe Efficacy and safety of NT 201 (botulinum neurotoxin free from complexing proteins) in blepharospasm Neurology 72 Suppl 3 2009 A346
63. J.K. Tsui, M. Hayward, E.K. Mak, and M. Schulzer Botulinum toxin type B in the treatment of cervical dystonia: a pilot study Neurology 45 11 1995 2109 2110
64. E.J. Pappert, and T. Germanson Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial Mov Disord 23 4 2008 510 517
65. C.L. Comella, J. Jankovic, K.M. Shannon, J. Tsui, M. Swenson, and S. Leurgans Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia Neurology 65 9 2005 1423 1429
66. R. Tintner, R. Gross, U.F. Winzer, K.A. Smalky, and J. Jankovic Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial Neurology 65 5 2005 765 767
67. D. Dressler, and H. Bigalke Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure J Neurol 252 8 2005 904 907
68. E.M. Quagliato, E.F. Carelli, and M.A. Viana A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia Clin Neuropharmacol 33 1 2010 22 26
69. X. Tang, and X. Wan Comparison of Botox with a Chinese type A botulinum toxin Chin Med J (Engl) 113 9 2000 794 798
70. E.M. Quagliato, E.F. Carelli, and M.A. Viana Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment Clin Neuropharmacol 33 1 2010 27 31
71. C.R. Rieder, P. Schestatsky, M.P. Socal, T.L. Monte, D. Fricke, and J. Costa A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm Clin Neuropharmacol 30 1 2007 39 42
72. Medy-Tox Inc Neuronox prescribing information 2006
73. J.S. Yoon, J.C. Kim, and S.Y. Lee Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm Korean J Ophthalmol 23 3 2009 137 141
74. D. Dressler Botulinum toxin for treatment of dystonia Eur J Neurol 17 Suppl 1 2010 88 96
75. C.L. Comella, A.S. Buchman, C.M. Tanner, N.C. Brown-Toms, and C.G. Goetz Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance Neurology 42 4 1992 878 882
76. M. Naumann, and J. Jankovic Safety of botulinum toxin type A: a systematic review and meta-analysis Curr Med Res Opin 20 7 2004 981 990
77. N.I. Mejia, K.D. Vuong, and J. Jankovic Long-term botulinum toxin efficacy, safety, and immunogenicity Mov Disord 20 5 2005 592 597
78. D. Charles, C. Adler, C. Comella, J. Jankovic, M. Stacy, and M. Kurth CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) - preliminary safety data [abstract] Mov Disord 25 Suppl 2 2010 S232
79. M. Kurth, C. Adler, C. Comella, D. Charles, J. Jankovic, and M. Stacy CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) - CD impact on quality of life (QOL) and patient reported outcomes (PRO) [abstract] Mov Disord 25 Suppl 2 2010 S229
80. S.J. Cano, T.T. Warner, J.M. Linacre, K.P. Bhatia, A.J. Thompson, and R. Fitzpatrick Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58) Neurology 63 9 2004 1629 1633
81. T.J. Anderson, J. Rivest, R. Stell, M.J. Steiger, H. Cohen, and P.D. Thompson Botulinum toxin treatment of spasmodic torticollis J R Soc Med 85 9 1992 524 529
82. G. Defazio, G. Abbruzzese, P. Girlanda, L. Vacca, A. Curra, and R. De Salvia Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study Arch Neurol 59 3 2002 418 420
83. D. Dressler Routine use of Xeomin in patients previously treated with Botox: long term results Eur J Neurol 16 Suppl 2 2009 2 5
84. G.Y. Hsiung, S.K. Das, R. Ranawaya, A.L. Lafontaine, and O. Suchowersky Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period Mov Disord 17 6 2002 1288 1293
85. M.F. Brin, C.L. Comella, J. Jankovic, F. Lai, and M. Naumann Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay Mov Disord 23 10 2008 1353 1360
86. P.J. Garcia-Ruiz, J.C. Castrillo, J.A. Burguera, V. Campos, A. Castro, and E. Cancho Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study J Neurol 258 6 2011 1055 1057
87. J. Jankovic, K.D. Vuong, and J. Ahsan Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia Neurology 60 7 2003 1186 1188
88. B. Berman, L. Seeberger, and R. Kumar Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia Mov Disord 20 2 2005 233 237
89. S.A. Factor, E.S. Molho, S. Evans, and P.J. Feustel Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia Mov Disord 20 9 2005 1152 1160
90. S.W. Hung, C. Hamani, A.M. Lozano, Y.Y. Poon, P. Piboolnurak, and J.M. Miyasaki Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia Neurology 68 6 2007 457 459
91. I.U. Isaias, R.L. Alterman, and M. Tagliati Deep brain stimulation for primary generalized dystonia: long-term outcomes Arch Neurol 66 4 2009 465 470
92. V. Braun, and H.P. Richter Selective peripheral denervation for spasmodic torticollis: 13-year experience with 155 patients J Neurosurg 97 Suppl 2 2002 207 212
93. A.A. Cohen-Gadol, J.E. Ahlskog, J.Y. Matsumoto, M.A. Swenson, R.L. McClelland, and D.H. Davis Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic J Neurosurg 98 6 2003 1247 1254
94. B. Ford, E.D. Louis, P. Greene, and S. Fahn Outcome of selective ramisectomy for botulinum toxin resistant torticollis J Neurol Neurosurg Psychiatry 65 4 1998 472 478
95. C. Cordivari, V.P. Misra, A. Vincent, S. Catania, K.P. Bhatia, and A.J. Lees Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test Mov Disord 21 10 2006 1737 1741